文献速递临床试验与 GCP

Liver-HERO:经颈静脉肝内门体分流术治疗肝硬化患者肝肾综合征-急性肾损伤的随机对照试验

Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial.
PubMed 文献 · Trials · 2023-04-05

肝硬化腹水患者易发生急性肾损伤,其中肝肾综合征-急性肾损伤(HRS-AKI)死亡率高,标准治疗为特利加压素联合白蛋白,但仅约半数患者可逆转。TIPS已用于静脉曲张出血和难治性腹水,在HRS-AKI中的应用存在争议。本研究为前瞻性多中心开放1:1随机对照平行组试验,主要终点为比较TIPS组与标准治疗组12个月无肝移植生存率。

要点

  • HRS-AKI标准治疗为特利加压素联合白蛋白,仅约半数患者可逆转。
  • TIPS在HRS-AKI中的应用存在争议,因HRS-AKI与心脏改变和慢加急性肝衰竭相关。
  • 本研究主要终点为12个月无肝移植生存率,TIPS应在随机化后72小时内放置。

核心结论

  • 研究假设TIPS在HRS-AKI患者中可能优于标准治疗。
  • 若试验显示TIPS组生存优势,该治疗可纳入HRS-AKI患者管理的常规临床实践。

研究设计与样本

  • 前瞻性、多中心、开放、1:1随机、对照平行组试验。
  • 患者确诊HRS-AKI后随机分配至TIPS组或标准治疗组。
  • TIPS应在72小时内放置;放置前TIPS组接受特利加压素和白蛋白治疗,放置后根据主治医师意见逐渐减停。
  • 主要终点为比较TIPS组与标准治疗组(特利加压素联合白蛋白)的12个月无肝移植生存率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with cirrhosis and ascites (and portal hypertension) are at risk of developing acute kidney injury (AKI). Although many etiologies exist, hepatorenal AKI (HRS-AKI) remains a frequent and difficult-to-treat cause, with a very high mortality when left untreated. The standard of care is the use of terlipressin and albumin. This can lead to reversal of AKI, which is associated to survival. Nevertheless, only approximately half of the patients achieve this reversal and even after reversal patients remains at risk for new episodes of HRS-AKI. TIPS is accepted for use in patients with variceal bleeding and refractory ascites, which leads to a reduction in portal pressure. Although preliminary data suggest it may be useful in HRS-AKI, its use in this setting is controversial and caution is recommended given the fact that HRS-AKI is associated to cardiac alterations and acute-on-chronic liver failure (ACLF) which represent relative contraindications for transjugular intrahepatic portosystemic shunt (TIPS). In the last decades, with the new definition of renal failure in patients with cirrhosis, patients are identified at an earlier stage. These patients are less sick and therefore more likely to not have contraindications for TIPS. We hypothesize that TIPS could be superior to the standard of care in patients with HRS-AKI. METHODS: This study is a prospective, multicenter, open, 1:1-randomized, controlled parallel-group trial. The main end-point is to compare the 12-month liver transplant-free survival in patients assigned to TIPS compared to the standard of care (terlipressin and albumin). Secondary end-point include reversal of HRS-AKI, health-related Quality of Life (HrQoL), and incidence of further decompensation among others. Once patients are diagnosed with HRS-AKI, they will be randomized to TIPS or Standard of Care (SOC). TIPS should be placed within 72 h. Until TIPS placement, TIPS patients will be treated with terlipressin and albumin. Once TIPS is placed, terlipressin and albumin should be weaned off according to the attending physician. DISCUSSION: If the trial were to show a survival advantage for patients who undergo TIPS placement, this could be incorporated in routine clinical practice in the management of patients with HRS-AKI. TRIAL REGISTRATION: Clinicaltrials.gov NCT05346393 . Released to the public on 01 April 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ripoll C, Platzer S, Franken P, et al. Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial. Trials. 2023. PMID: 37020315. doi:10.1186/s13063-023-07261-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。